Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Global Scams Remain Widespread: Nearly Two in Three Adults Worldwide Report Scam Encounters, 9% Lost Money

    November 19, 2026

    UnionPay International and Transsion Announce Global Partnership to Bring UnionPay Payments to T Wallet, Debuting in Pakistan

    November 19, 2026

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026
    Jeddah JournalJeddah Journal
    • Automotive
    • Business
    • Entertainment
    • Health
    • Luxury
    • Lifestyle
    • News
    • Sports
    • Technology
    • Travel
    Jeddah JournalJeddah Journal
    Home » Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment
    ACCESS Newswire

    Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment

    February 4, 2025
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    With Northway Biotech’s expertise in biologics manufacturing, Mallia aims to enter the multi-billion-dollar alopecia market by delivering a safe and effective topical sCD83 treatment designed to stimulate hair follicle formation and promote sustained hair growth.

    ERLANGEN, GERMANY AND VILNIUS, LITHUANIA / ACCESS Newswire / February 4, 2025 / Mallia Therapeutics (“Mallia”), a biopharmaceutical company developing novel treatments for hair loss, and Northway Biotech (“NBT”), a biologics Contract Development and Manufacturing Organization (CDMO), have announced a partnership for the development of the production process and manufacturing of Mallia’s soluble CD83 protein (sCD83), a treatment aimed at promoting hair follicle formation and growth.

    Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop the production process for the recombinant sCD83 protein for large-scale production, utilizing the Pichia pastoris expression system. This collaboration includes the development of analytical methods, technology scale-up, and the manufacturing of a cGMP Drug Substance.

    Dr. Manfred Groeppel, co-founder and Managing Director of Mallia Therapeutics, said: “With this partnership, we are advancing the development of sCD83 to turn our research into a scalable treatment for patients.”

    “Interestingly, sCD83’s mode of action induces both the formation of new hair follicles and thus hair growth, and has the potential to redefine treatment approaches for hormone-induced androgenetic alopecia as well as immune-mediated alopecia areata,” emphasizes Prof. Dr. Alexander Steinkasserer, co-founder and Managing Director of Mallia. “By developing a robust production process, we are ensuring the quality required for future clinical as well as commercial applications.”

    Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech, expressed, “We are excited to be working with Mallia on developing the manufacturing process of sCD83. Our priority is to ensure the highest manufacturing standards and maintain clear, open communication as we collaborate every step of the way.”

    “Mallia’s team and their innovative solution make this project particularly appealing to us given its huge potential and the large need from people all over the world for treatment. The strong and transparent collaboration we have established allows us to support Mallia with confidence as we move forward together quickly,”added André Markmann, PhD, VP of Business Development at Northway Biotech.

    About Mallia Therapeutics GmbH

    Mallia Therapeutics GmbH is a biopharmaceutical company focused on developing novel treatments for patients suffering from hair loss. The Company was founded in 2023 in Erlangen, Germany, and is led by an experienced management team and worldwide leading experts in the field of CD83, with more than 60 CD83-related publications and 20 years of experience in the field.

    With sCD83, a potential treatment for hair loss in preclinical development, Mallia aims to enter the multi-billion-dollar alopecia market and provide patients with a safe and effective topical treatment.

    Connect with us on LinkedIn or find out more here: https://mallia-therapeutics.com/

    About Northway Biotech

    Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced and professional team executes projects at every stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company’s extensive expertise and vertically integrated service offering enable rapid execution of multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and operates locations in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA. For more information, please visit www.northwaybiotech.com.

    Mallia Therapeutics Contact:

    Mallia Therapeutics GmbH
    info@mallia-therapeutics.com

    International Media Contact:

    MC Services AG
    Dr. Regina Lutz / Katja Arnold
    Tel.: +49 (0)89 210 228 0
    E-Mail: mallia-therapeutics@mc-services.eu

    Contact Information

    Vladas Bumelis
    CEO and Chairman of the Board
    vladas.bumelis@northwaybiotech.com

    SOURCE: Northway Biotech

    View the original press release on ACCESS Newswire

    Related Posts

    Global Scams Remain Widespread: Nearly Two in Three Adults Worldwide Report Scam Encounters, 9% Lost Money

    November 19, 2026

    Chevron Signs 3-Year Agreement with UptimeAI, Scaling Expertise to Enhance Asset Reliability and Operational Efficiency

    November 17, 2026

    ARC Names UptimeAI Leader in 2026 MarketMap for Industrial Copilots – Plant Operations

    November 2, 2026

    Chervon Promotes Soobia Haroon to Vice President, Human Resources – NA

    November 2, 2026

    IAVI Awarded $36 Million From BARDA for Bundibugyo Virus Vaccine Development

    October 28, 2026

    Formerra Adjusts Transportation Surcharge Amid Continued Freight and Logistics Pressures

    October 27, 2026
    Latest News

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Congo Ebola death toll reaches 5,568 as cases pass 11,000

    November 18, 2026

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026

    Prabowo says DEFA can unlock $2 trillion ASEAN digital economy

    November 18, 2026

    Tunisia tourism revenues top $2.38 billion by end-October

    November 17, 2026

    UAE President and Venezuela’s acting leader discuss closer ties

    November 17, 2026
    © 2026 Jeddah Journal | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.